Abstract 1130P
Background
Tebe, a bispecific T-cell engager, showed a benefit in response rate, progression-free survival (PFS) and overall survival (OS) in HLA A*02-01pos mUM pts in the IMCgp100-202 phase III trial. Prior to approval, French Health Authorities allowed an early access to Tebe in May 2021 to mUM pts. We report here our real-world experience with Tebe and analyses of potential prognostic and predictive biomarkers.
Methods
Ongoing ambispective cohort of mUM pts treated with Tebe. Tumor sizes were evaluated according to RECIST 1.1. Circulating tumor DNA (ctDNA) analyses were performed on this cohort and on the 18 pts enrolled in the IMCgp100-202 trial and randomized to Tebe, at Institut Curie. ctDNA was measured by digital droplet PCR (ddPCR) targeting codons 183 & 209 of both GNAQ and GNA11.
Results
72 pts were included from May 26th 2021 to December 12th 2022. With a median follow-up of 48 weeks, patients received a median of 22 weeks of Tebe. Out of 60 assessable pts, 33 (55%) showed stable disease and 5 (8%) partial response according to RECIST 1.1. Median PFS (mPFS) was 28 weeks (confidence interval 95% [CI95]: 8-56). OS at 12 months (OS12m) was 72%. No new, unexpected safety event occurred. Elevated baseline LDH was correlated with poorer OS (Spearman rho= -0.26, p<0.01). 63 pts had mUM carrying somatic mutations detectable by ddPCR (ie GNAQ/GNA11 mutations). Of these, 39 pts (62%) had detectable ctDNA at baseline. Pts with detectable ctDNA at baseline had poorer PFS (mPFS 4.0 vs 14.0 months; HR=2.83, CI95[1.48-5.41]) and OS (OS12m of 51.5% vs 95.4%; HR=6.11, CI95[2.04-18.3]) than those with undetectable ctDNA. 22 pts cleared their ctDNA at first assessment (12 weeks) and had numerically better OS12m than those who did not (70% vs 60%; HR = 1.83 CI95[0.92-13.9]).
Conclusions
In this real-world cohort of mUM pts, Tebe is associated with clinical outcomes in lin withthe IMCgp100-202 trial. Baseline ctDNA and LDH are prognostic factors while ctDNA clearance might predict benefit from Tebe. Other analyses are ongoing to identify new predictive biomarkers.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
INSERM.
Disclosure
M. Saint-Ghislain: Financial Interests, Invited Speaker: Oncotream. J. Thery: Financial Interests, Invited Speaker: PharmaMar; Financial Interests, Advisory Board: Pfizer, AstraZeneca. P. Combe: Financial Interests, Invited Speaker: Eisai, BMS GmbH&Co.KG, Novartis, Clovis Oncology, AstraZeneca. C. Dutriaux: Financial Interests, Advisory Board: Bristol Myers Squibb, MSD, Pierre Fabre. S. Piperno-Neumann: Financial Interests, Personal, Advisory Board: Immunocore, Pierre Fabre, Atlanthera. M.J. Rodrigues: Financial Interests, Personal, Invited Speaker: Immunocore; Financial Interests, Personal, Advisory Board: GSK, AstraZeneca; Financial Interests, Institutional, Coordinating PI: Johnson & Johnson; Non-Financial Interests, Institutional, Product Samples: MSD. All other authors have declared no conflicts of interest.
Resources from the same session
1109P - Second-line pembrolizumab (pembro) in Chinese patients (pts) with advanced melanoma: Long-term follow-up of the phase I KEYNOTE-151 study
Presenter: Lu Si
Session: Poster session 13
1110P - A phase II clinical trial of SHR-1701 combined with temozolomide for advanced melanoma
Presenter: Tu Hu
Session: Poster session 13
1111P - A randomised phase II study of intermittent versus continuous dosing of targeted therapy in patients with BRAFV600 mutant advanced melanoma (INTERIM)
Presenter: Avinash Gupta
Session: Poster session 13
1112P - Five-year survival after intermittent targeted therapy and anti-PD1 in stage IV melanoma: An update of the IMPemBra trial
Presenter: Lotte Hoeijmakers
Session: Poster session 13
1113P - COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (enco) + binimetinib (bini) vs vemurafenib (vemu) or enco in patients (pts) with BRAF V600–mutant melanoma
Presenter: Dirk Schadendorf
Session: Poster session 13
1114P - Encorafenib (E) plus binimetinib (B) in unresectable advanced or metastatic BRAFV600-mut melanoma, real-world evidence in Spain (GEM 2002 - BECARE)
Presenter: Ainara Soria Rivas
Session: Poster session 13
1115P - Comparison of efficacy and toxicity of dabrafenib/trametinib versus vemurafenib/cobimetinib therapy in routine medical practice: Eight years of BRAF/MEK inhibitor use in routine clinical practice
Presenter: Karolina Piejko
Session: Poster session 13
1116P - Long term outcome of complete responders to immune checkpoint inhibitors (ICI) or target therapy (TT) in advanced melanoma
Presenter: Celine Boutros
Session: Poster session 13
1117P - Overall survival (OS) in patients with metastatic BRAF V600-mutant melanoma treated with encorafenib plus binimetinib (ENCO+BINI): Comparing real-world vs clinical trial data
Presenter: Gino In
Session: Poster session 13
1118P - Real-world treatment patterns and outcomes among patients with BRAF+ metastatic melanoma refractory to first-line immunotherapy
Presenter: Thach-Giao Truong
Session: Poster session 13